According to our (Global Info Research) latest study, the global Ocrelizumab market size was valued at US$ 1015 million in 2025 and is forecast to a readjusted size of US$ 3388 million by 2032 with a CAGR of 14.6% during review period.
In 2025, global production of Obinutuzumab reached approximately 8.6 million units.Ocrelizumab is a humanized monoclonal antibody primarily used for the treatment of Multiple Sclerosis (MS), including Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS). It works by targeting and inhibiting the activity of B cells, reducing the immune system's attack on the central nervous system, thereby slowing disease progression and reducing relapses. Ocrelizumab is administered via intravenous injection, typically once every six months. The drug has been approved for clinical use in multiple countries and regions, particularly for MS patients who have not responded well to other treatment options.、
Ocrelizumab is a first-line biologic pharmaceutical drug for the treatment of Multiple Sclerosis (MS), and holds an important position in the global market. With the increasing early diagnosis rates of MS, the demand for effective treatments is steadily rising, leading to growing market demand for Ocrelizumab. Particularly in the treatment of Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS), Ocrelizumab has gradually become a key treatment choice due to its significant efficacy and relatively low side effects.The market prospects for Ocrelizumab are very promising, especially in developed countries and regions, where its excellent efficacy and dosing schedule of once every 6 months greatly improve patient compliance, making it highly favored by both patients and doctors. However, despite its significant therapeutic advantages, the high price of the drug may limit its accessibility in some countries or regions with lower economic conditions.
This report is a detailed and comprehensive analysis for global Ocrelizumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Ocrelizumab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Ocrelizumab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Ocrelizumab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Ocrelizumab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Ocrelizumab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Ocrelizumab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Genentech, F. Hoffmann-La Roche, Chugai, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Ocrelizumab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
100 mg/10 mL
300 mg/10 mL
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Combination Therapy
Obinutuzumab In Combination With Chlorambucil
Obinutuzumab Combined With Bendamustine
Market segment by Application
Relapsing Remitting Multiple Sclerosis (RRMS)
Primary Progressive Multiple Sclerosis (PPMS)
Others
Major players covered
Genentech
F. Hoffmann-La Roche
Chugai
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Ocrelizumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Ocrelizumab, with price, sales quantity, revenue, and global market share of Ocrelizumab from 2021 to 2026.
Chapter 3, the Ocrelizumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Ocrelizumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Ocrelizumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Ocrelizumab.
Chapter 14 and 15, to describe Ocrelizumab sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Ocrelizumab. Industry analysis & Market Report on Ocrelizumab is a syndicated market report, published as Global Ocrelizumab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Ocrelizumab market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.